The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nasreen, M.
Right arrow Articles by Takahama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nasreen, M.
Right arrow Articles by Takahama, Y.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
The Journal of Immunology, 2003, 171: 3394-3400.
Copyright © 2003 by The American Association of Immunologists

In Vivo Treatment of Class II MHC-Deficient Mice with Anti-TCR Antibody Restores the Generation of Circulating CD4 T Cells and Optimal Architecture of Thymic Medulla 1

Mariam Nasreen*, Tomoo Ueno{dagger}, Fumi Saito{dagger} and Yousuke Takahama2,*,{dagger}

* Division of Experimental Immunology, Institute for Genome Research, University of Tokushima, and {dagger} Laboratory of Immune System Development, The Institute of Physical and Chemical Research (RIKEN), Research Center for Allergy and Immunology, Tokushima, Japan

TCR ligation by the self-peptide-associated MHC molecules is essential for T cell development in the thymus, so that class II MHC-deficient mice do not generate CD4+CD8- T cells. The present results show that the administration of anti-TCR mAb into class II MHC-deficient mice restores the generation of CD4+CD8- T cells in vivo. The CD4 T cells were recovered in the thymus, peripheral blood, and the spleen, indicating that the anti-TCR treatment is sufficient for peripheral supply of newly generated CD4 T cells. Unlike peripheral CD4 T cells that disappeared within 5 wk after the treatment, CD4+CD8- thymocytes remained undiminished even after 5 wk, suggesting that CD4 T cells in the thymus are maintained separately from circulating CD4 T cells and even without class II MHC molecules. It was also found that the mass of medullary region in the thymus, which was reduced in class II MHC-deficient mice, was restored by the anti-TCR administration, suggesting that the medulla for CD4+CD8- thymocytes is formed independently of the medulla for CD4-CD8+ thymocytes. These results indicate that in vivo anti-TCR treatment in class II MHC-deficient mice restores the generation of circulating CD4 T cells and optimal formation of the medulla in the thymus, suggesting that anti-TCR Ab may be useful for clinical treatment of class II MHC deficiencies.




This article has been cited by other articles:


Home page
Int ImmunolHome page
J. Gui, X. Zhu, J. Dohkan, L. Cheng, P. F. Barnes, and D.-M. Su
The aged thymus shows normal recruitment of lymphohematopoietic progenitors but has defects in thymic epithelial cells
Int. Immunol., October 1, 2007; 19(10): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. H. D. Gray, N. Seach, T. Ueno, M. K. Milton, A. Liston, A. M. Lew, C. C. Goodnow, and R. L. Boyd
Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells
Blood, December 1, 2006; 108(12): 3777 - 3785.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
T. Ueno, F. Saito, D. H.D. Gray, S. Kuse, K. Hieshima, H. Nakano, T. Kakiuchi, M. Lipp, R. L. Boyd, and Y. Takahama
CCR7 Signals Are Essential for Cortex-Medulla Migration of Developing Thymocytes
J. Exp. Med., August 16, 2004; 200(4): 493 - 505.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.